10-Q 1 dtil-10q_20220331.htm Q3 2022 10-Q dtil-10q_20220331.htm
false Q1 2022 PRECISION BIOSCIENCES INC 0001357874 --12-31 P1Y P6Y29D P6Y5M4D 0001357874 2022-01-01 2022-03-31 xbrli:shares 0001357874 2022-05-03 iso4217:USD 0001357874 2022-03-31 0001357874 2021-12-31 iso4217:USD xbrli:shares 0001357874 2021-01-01 2021-03-31 0001357874 us-gaap:CommonStockMember 2020-12-31 0001357874 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001357874 us-gaap:RetainedEarningsMember 2020-12-31 0001357874 us-gaap:TreasuryStockMember 2020-12-31 0001357874 2020-12-31 0001357874 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001357874 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001357874 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001357874 us-gaap:CommonStockMember 2021-03-31 0001357874 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001357874 us-gaap:RetainedEarningsMember 2021-03-31 0001357874 us-gaap:TreasuryStockMember 2021-03-31 0001357874 2021-03-31 0001357874 us-gaap:CommonStockMember 2021-12-31 0001357874 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001357874 us-gaap:RetainedEarningsMember 2021-12-31 0001357874 us-gaap:TreasuryStockMember 2021-12-31 0001357874 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001357874 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001357874 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001357874 us-gaap:CommonStockMember 2022-03-31 0001357874 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001357874 us-gaap:RetainedEarningsMember 2022-03-31 0001357874 us-gaap:TreasuryStockMember 2022-03-31 0001357874 dtil:PrecisionPlantSciencesIncMember 2022-01-01 2022-03-31 xbrli:pure 0001357874 dtil:PrecisionPlantSciencesIncMember 2022-03-31 0001357874 dtil:PrecisionBioSciencesUKLimitedMember 2022-03-31 0001357874 dtil:PrecisionBioSciencesUKLimitedMember 2022-01-01 2022-03-31 0001357874 srt:MaximumMember 2022-01-01 2022-03-31 0001357874 2019-04-01 0001357874 dtil:TwoThousandSixAndTwoThousandFifteenStockIncentivePlanMember 2022-03-31 0001357874 dtil:TwoThousandNineteenIncentiveAwardPlanMember 2019-03-12 0001357874 dtil:TwoThousandNineteenIncentiveAwardPlanMember 2022-03-31 0001357874 dtil:TwoThousandNineteenIncentiveAwardPlanMember 2019-03-11 2019-03-12 0001357874 dtil:TwoThousandNineteenIncentiveAwardPlanMember us-gaap:RestrictedStockUnitsRSUMember 2022-03-31 0001357874 dtil:TwoThousandNineteenEmployeeStockPurchasePlanMember 2019-03-12 0001357874 dtil:TwoThousandNineteenEmployeeStockPurchasePlanMember 2022-03-31 0001357874 dtil:TwoThousandNineteenEmployeeStockPurchasePlanMember 2019-03-11 2019-03-12 0001357874 dtil:TwoThousandNineteenEmployeeStockPurchasePlanMember dtil:EmployeeStockPurchasePlanMember 2019-03-12 0001357874 dtil:EmployeeStockPurchasePlanMember srt:MaximumMember 2022-01-01 2022-03-31 0001357874 dtil:EmployeeStockPurchasePlanMember srt:MaximumMember 2021-01-01 2021-03-31 0001357874 dtil:InducementAwardPlanMember srt:MaximumMember 2021-08-09 0001357874 dtil:InducementAwardPlanMember 2022-03-31 0001357874 dtil:InducementAwardPlanMember us-gaap:RestrictedStockUnitsRSUMember 2022-03-31 0001357874 us-gaap:ShareBasedPaymentArrangementEmployeeMember 2022-01-01 2022-03-31 0001357874 us-gaap:ShareBasedPaymentArrangementEmployeeMember 2021-01-01 2021-03-31 0001357874 us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2022-01-01 2022-03-31 0001357874 us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2021-01-01 2021-03-31 0001357874 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:EmployeeStockOptionMember 2022-01-01 2022-03-31 0001357874 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:EmployeeStockOptionMember 2021-01-01 2021-03-31 0001357874 us-gaap:GeneralAndAdministrativeExpenseMember us-gaap:EmployeeStockOptionMember 2022-01-01 2022-03-31 0001357874 us-gaap:GeneralAndAdministrativeExpenseMember us-gaap:EmployeeStockOptionMember 2021-01-01 2021-03-31 0001357874 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-03-31 0001357874 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-03-31 0001357874 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-03-31 0001357874 us-gaap:RestrictedStockUnitsRSUMember 2021-12-31 0001357874 us-gaap:RestrictedStockUnitsRSUMember 2022-03-31 0001357874 dtil:ContractLiabilitiesMember 2022-03-31 0001357874 dtil:ContractLiabilitiesMember 2021-12-31 0001357874 srt:MaximumMember 2021-04-09 2021-04-09 0001357874 dtil:SupplyAgreementsMember 2022-01-01 2022-03-31 0001357874 us-gaap:RevolvingCreditFacilityMember dtil:PacificWesternLoanAgreementMember 2019-05-31 0001357874 dtil:PacificWesternLoanAgreementMember srt:MinimumMember us-gaap:RevolvingCreditFacilityMember 2022-03-31 0001357874 dtil:PacificWesternLoanAgreementMember us-gaap:RevolvingCreditFacilityMember 2022-01-01 2022-03-31 0001357874 dtil:PacificWesternLoanAgreementMember us-gaap:RevolvingCreditFacilityMember 2022-03-31 0001357874 us-gaap:RevolvingCreditFacilityMember dtil:PacificWesternLoanAgreementMember 2021-12-01 2021-12-31 0001357874 srt:ScenarioForecastMember 2022-01-01 2022-12-31 0001357874 dtil:EquityIssuanceAgreementMember dtil:IECUREMember 2022-03-31 0001357874 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2022-03-31 0001357874 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2022-03-31 0001357874 us-gaap:FairValueMeasurementsRecurringMember dtil:InvestmentInIECUREMember 2022-03-31 0001357874 us-gaap:FairValueMeasurementsRecurringMember dtil:InvestmentInIECUREMember us-gaap:FairValueInputsLevel3Member 2022-03-31 0001357874 us-gaap:FairValueMeasurementsRecurringMember 2022-03-31 0001357874 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2022-03-31 0001357874 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2022-03-31 0001357874 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2021-12-31 0001357874 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2021-12-31 0001357874 us-gaap:FairValueMeasurementsRecurringMember dtil:InvestmentInIECUREMember 2021-12-31 0001357874 us-gaap:FairValueMeasurementsRecurringMember dtil:InvestmentInIECUREMember us-gaap:FairValueInputsLevel3Member 2021-12-31 0001357874 us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001357874 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2021-12-31 0001357874 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2021-12-31 0001357874 dtil:PromissoryNoteMember dtil:NewEloMember 2021-12-17 0001357874 dtil:PromissoryNoteMember dtil:NewEloMember 2021-12-17 2021-12-17 0001357874 dtil:NewEloMember 2021-12-17 0001357874 dtil:NewEloMember 2022-01-01 2022-03-31 0001357874 us-gaap:ResearchAndDevelopmentArrangementMember dtil:EliLillyAndCompanyMember 2021-01-06 2021-01-06 0001357874 us-gaap:ResearchAndDevelopmentArrangementMember dtil:EliLillyAndCompanyMember dtil:StockPurchaseAgreementMember 2021-01-06 0001357874 us-gaap:ResearchAndDevelopmentArrangementMember dtil:EliLillyAndCompanyMember dtil:StockPurchaseAgreementMember 2021-01-06 2021-01-06 0001357874 dtil:EliLillyAndCompanyMember us-gaap:ResearchAndDevelopmentArrangementMember 2022-01-01 2022-03-31 0001357874 dtil:EliLillyAndCompanyMember us-gaap:ResearchAndDevelopmentArrangementMember 2021-01-01 2021-03-31 0001357874 dtil:EliLillyAndCompanyMember us-gaap:ResearchAndDevelopmentArrangementMember 2022-03-31 0001357874 dtil:EliLillyAndCompanyMember us-gaap:ResearchAndDevelopmentArrangementMember 2021-12-31 0001357874 dtil:EliLillyAndCompanyMember us-gaap:ResearchAndDevelopmentArrangementMember dtil:CurrentLiabilitiesMember 2022-03-31 0001357874 dtil:EliLillyAndCompanyMember us-gaap:ResearchAndDevelopmentArrangementMember dtil:CurrentLiabilitiesMember 2021-12-31 0001357874 dtil:IECUREMember us-gaap:ResearchAndDevelopmentArrangementMember 2021-08-31 0001357874 dtil:IECUREMember us-gaap:ResearchAndDevelopmentArrangementMember 2022-03-31 0001357874 dtil:IECUREMember us-gaap:ResearchAndDevelopmentArrangementMember 2022-01-01 2022-03-31 0001357874 dtil:ProgramPurchaseAgreementMember dtil:ServierMember 2021-04-09 2021-04-09 0001357874 dtil:DevelopmentAndCommercialLicenseAgreementMember dtil:ServierMember 2022-01-01 2022-03-31 0001357874 dtil:DevelopmentAndCommercialLicenseAgreementMember dtil:ServierMember 2021-01-01 2021-03-31 0001357874 dtil:DevelopmentAndCommercialLicenseAgreementMember dtil:ServierMember 2022-03-31 0001357874 dtil:DevelopmentAndCommercialLicenseAgreementMember dtil:ServierMember 2021-12-31 0001357874 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-03-31 0001357874 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-03-31 0001357874 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-03-31 0001357874 dtil:UnsettledEmployeeStockPurchasePlanContributionsMember 2022-01-01 2022-03-31 0001357874 dtil:UnsettledEmployeeStockPurchasePlanContributionsMember 2021-01-01 2021-03-31 dtil:Segment

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 10-Q

 

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2022

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number: 001-38841

 

Precision BioSciences, Inc.

(Exact Name of Registrant as Specified in its Charter)

 

 

Delaware

20-4206017

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification No.)

302 East Pettigrew St., Suite A-100

Durham, North Carolina

27701

(Address of principal executive offices)

(Zip Code)

 

(919) 314-5512

(Registrant’s telephone number, including area code)

 

N/A

(Former name, former address and former fiscal year, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Act:

 

 

 

 

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.000005 per share

DTIL

The Nasdaq Global Select Market

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.     Yes      No  

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes      No  

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

 

Accelerated filer

 

Non-accelerated filer

 

Smaller reporting company

 

 

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes      No 

As May 3, 2022, the registrant had 62,176,408 shares of common stock, $0.000005 par value per share, outstanding.

 

 

 


 

Table of Contents

 

 

 

Page

 

Forward-Looking Statements

3

 

Risk Factor Summary

5

PART I.

FINANCIAL INFORMATION

6

Item 1.

Financial Statements

6

 

Condensed Consolidated Balance Sheets

6

 

Condensed Consolidated Statements of Operations

7

 

Condensed Consolidated Statements of Changes in Stockholders’ Equity

8

 

Condensed Consolidated Statements of Cash Flows

9

 

Notes to Unaudited Condensed Consolidated Financial Statements

10

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

21

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

32

Item 4.

Controls and Procedures

32

PART II.

OTHER INFORMATION

33

Item 1.

Legal Proceedings

33

Item 1A.

Risk Factors

33

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

82

Item 3.

Defaults Upon Senior Securities

82

Item 4.

Mine Safety Disclosures

82

Item 5.

Other Information

82

Item 6.

Exhibits

83

 

Signatures

84

 

 

 

 

 


2


 

 

FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements other than statements of present and historical facts contained in this Quarterly Report on Form 10-Q, including without limitation, statements regarding our future results of operations and financial position, business strategy and approach, including related results, prospective products, planned preclinical studies and clinical trials, or discontinuance thereof, the status and results of our preclinical and clinical studies, including, the potential of our product candidates, if approved, to become best-in-class or first-in-class, expected release of interim data, expectations regarding our allogeneic chimeric antigen receptor T cell immunotherapy product candidates, expectations regarding the use and effects of ARCUS, including in connection with in vivo genome editing, potential new partnerships or alternative opportunities for our product candidates, capabilities of our manufacturing facility, potential new application filings and regulatory approvals, research and development costs, timing, expected results and likelihood of success, plans and objectives of management for future operations, as well as the impact of the COVID-19 pandemic and variants thereof may be forward-looking statements. Without limiting the foregoing, in some cases, you can identify forward-looking statements by terms such as “aim,” “may,” “will,” “should,” “expect,” “exploring,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential,” “seeks,” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. No forward-looking statement is a guarantee of future results, performance, or achievements, and one should avoid placing undue reliance on such statements.

Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to us. Such beliefs and assumptions may or may not prove to be correct. Additionally, such forward-looking statements are subject to a number of known and unknown risks, uncertainties and assumptions, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including, but not limited to, those identified in Part II. Item 1A. “Risk Factors” and Part I. Item 2. “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” These risks and uncertainties include, but are not limited to:

 

our ability to become profitable;

 

our ability to procure sufficient funding and requirements under our current debt instruments and effects of restrictions thereunder;

 

risks associated with raising additional capital;

 

our operating expenses and our ability to predict what those expenses will be;

 

our limited operating history;

 

the success of our programs and product candidates in which we expend our resources;

 

our dependence on our ARCUS technology;

 

the risk that other genome-editing technologies may provide significant advantages over our ARCUS technology;

 

the initiation, cost, timing, progress, achievement of milestones and results of research and development activities and preclinical and clinical studies;

 

public perception about genome editing technology and its applications;

 

competition in the genome editing, biopharmaceutical, and biotechnology fields;

 

our or our collaborators’ ability to identify, develop and commercialize product candidates;

 

pending and potential liability lawsuits and penalties against us or our collaborators related to our technology and our product candidates;

 

the U.S. and foreign regulatory landscape applicable to our and our collaborators’ development of product candidates;

 

our or our collaborators’ ability to obtain and maintain regulatory approval of our product candidates, and any related restrictions, limitations and/or warnings in the label of an approved product candidate;

3


 

our or our collaborators’ ability to advance product candidates into, and successfully design, implement and complete, clinical trials;

 

potential manufacturing problems associated with the development or commercialization of any of our product candidates;

 

our ability to obtain an adequate supply of T cells from qualified donors;

 

our ability to achieve our anticipated operating efficiencies at our manufacturing facility;

 

delays or difficulties in our and our collaborators’ ability to enroll patients;

 

changes in interim “top-line” data that we announce or publish;

 

if our product candidates do not work as intended or cause undesirable side effects;

 

risks associated with applicable healthcare, data privacy and security regulations and our compliance therewith;

 

the rate and degree of market acceptance of any of our product candidates;

 

the success of our existing collaboration agreements and our ability to enter into new collaboration arrangements;

 

our current and future relationships with third parties including suppliers and manufacturers;

 

our ability to obtain and maintain intellectual property protection for our technology and any of our product candidates;

 

potential litigation relating to infringement or misappropriation of intellectual property rights;

 

our ability to effectively manage the growth of our operations;

 

our ability to attract, retain, and motivate key scientific and management personnel;

 

market and economic conditions;

 

effects of system failures and security breaches;

 

effects of natural and manmade disasters, public health emergencies and other natural catastrophic events;

 

effects of the COVID-19 pandemic and variants thereof, or any pandemic, epidemic, or outbreak of an infectious disease;

 

insurance expenses and exposure to uninsured liabilities;

 

effects of tax rules; and

 

risks related to ownership of our common stock, including fluctuations in our stock price.

Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties.

You should read this Quarterly Report on Form 10-Q and the documents that we reference herein completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements. All forward-looking statements contained herein speak only as of the date of this Quarterly Report on Form 10-Q. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

As used in this Quarterly Report on Form 10-Qs, unless otherwise stated or the context requires otherwise, references to “Precision,” the “Company,” “we,” “us,” and “our,” refer to Precision BioSciences, Inc. and its subsidiaries on a consolidated basis.


4


 

 

RISK FACTOR SUMMARY

Our business is subject to numerous risks and uncertainties, including those described in Part II. Item 1A. “Risk Factors” in this Quarterly Report on Form 10-Q. You should carefully consider these risks and uncertainties when investing in our common stock. Some of the principal risks and uncertainties include the following.

 

We have incurred significant operating losses since our inception and expect to continue to incur losses for the foreseeable future. We have not been profitable and may not achieve or maintain profitability.

 

We will need substantial additional funding, and if we are unable to raise a sufficient amount of capital when needed on acceptable terms, or at all, we may be forced to delay, reduce or eliminate some or all of our research programs, product development activities and commercialization efforts.

 

We have a limited operating history, which makes it difficult to evaluate our current business and future prospects and may increase the risk of your investment.

 

ARCUS is a novel technology, making it difficult to predict the time, cost and potential success of product candidate development. We have not yet been able to assess the safety and efficacy of most of our product candidates in humans and have only limited safety and efficacy information in humans to date regarding three of our product candidates.

 

We are heavily dependent on the successful development and translation of ARCUS, and due to the early stages of our product development operations, we cannot give any assurance that any product candidates will be successfully developed and commercialized.

 

Adverse public perception of genome editing may negatively impact the developmental progress or commercial success of products that we develop alone or with collaborators.

 

We face significant competition in industries experiencing rapid technological change, and there is a possibility that our competitors may achieve regulatory approval before us or develop product candidates or treatments that are safer or more effective than ours, which may harm our financial condition and our ability to successfully market or commercialize any of our product candidates.

 

Our future profitability, if any, will depend in part on our ability and the ability of our collaborators to commercialize any products that we or our collaborators may develop in markets throughout the world. Commercialization of products in various markets could subject us to risks and uncertainties.

 

Product liability lawsuits against us could cause us to incur substantial liabilities and could limit commercialization of any products that we develop alone or with collaborators.

 

The regulatory landscape that will apply to development of therapeutic product candidates by us or our collaborators is rigorous, complex, uncertain and subject to change, which could result in delays or termination of development of such product candidates or unexpected costs in obtaining regulatory approvals.

 

Clinical trials are difficult to design and implement, expensive, time-consuming and involve an uncertain outcome, and the inability to successfully and timely conduct clinical trials and obtain regulatory approval for our product candidates would substantially harm our business.

 

Any product candidates that we or our collaborators may develop will be novel and may be complex and difficult to manufacture, and if we experience manufacturing problems, it could result in delays in development and commercialization of such product candidates or otherwise harm our business.

 

Even if we obtain regulatory approval for any products that we develop alone or with collaborators, such products will remain subject to ongoing regulatory requirements, which may result in significant additional expense.

 

Even if any product we develop alone or with collaborators receives marketing approval, such product may fail to achieve the degree of market acceptance by physicians, patients, healthcare payors and others in the medical community necessary for commercial success.

 

The ongoing novel coronavirus disease, COVID-19 has impacted, and may continue to impact, our business, and any other pandemic, epidemic or outbreak of an infectious disease may materially and adversely impact our business, including our preclinical studies and clinical trials.

5


Part I. Financial information

 

Item 1.  Financial Statements.

Precision Biosciences, Inc.

Condensed Consolidated Balance Sheets

(In thousands, except share and per share amounts)

(Unaudited)

 

 

 

March 31, 2022

 

 

December 31, 2021

 

Assets

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

116,222

 

 

$

143,663

 

Accounts receivable

 

 

488

 

 

 

488

 

Prepaid expenses

 

 

17,060

 

 

 

17,434

 

Other current assets

 

 

283

 

 

 

169

 

Total current assets

 

 

134,053

 

 

 

161,754

 

Property, equipment, and software—net

 

 

23,874

 

 

 

25,154

 

Intangible assets—net

 

 

2,021

 

 

 

2,048

 

Right-of-use assets—net

 

 

3,892

 

 

 

4,180

 

Investment in equity securities

 

 

3,091

 

 

 

3,091

 

Equity method investments

 

 

2,799

 

 

 

3,751

 

Note receivable—net

 

 

6,966

 

 

 

6,879

 

Other assets

 

 

4,655

 

 

 

4,641

 

Total assets

 

$

181,351

 

 

$

211,498

 

Liabilities and Stockholders’ Equity

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

Accounts payable

 

$

699

 

 

$

1,144

 

Accrued compensation

 

 

3,154

 

 

 

6,765

 

Accrued clinical and research and development expenses

 

 

2,073

 

 

 

4,028

 

Deferred revenue

 

 

19,686

 

 

 

21,244

 

Lease liabilities

 

 

1,874

 

 

 

1,822

 

Other current liabilities

 

 

1,620

 

 

 

977

 

Total current liabilities

 

 

29,106

 

 

 

35,980

 

Deferred revenue

 

 

65,743

 

 

 

67,015

 

Lease liabilities

 

 

4,327

 

 

 

4,813

 

Long term debt—net

 

 

2,482

 

 

 

2,478

 

Contract liabilities

 

 

10,000

 

 

 

10,000

 

Other noncurrent liabilities

 

 

34

 

 

 

44

 

Total liabilities

 

 

111,692

 

 

 

120,330

 

Commitments and contingencies (Note 4)

 

 

 

 

 

 

 

 

Stockholders’ equity:

 

 

 

 

 

 

 

 

Preferred stock, $0.0001 par value— 10,000,000 shares authorized as of March 31, 2022 and December 31, 2021; no shares issued and outstanding as of March 31, 2022 and December 31, 2021

 

 

 

 

 

 

Common stock; $0.000005 par value— 200,000,000 shares authorized as of March 31, 2022 and December 31, 2021; 62,585,043 shares issued and 61,774,571 shares outstanding as of March 31, 2022; 61,712,577 shares issued and 60,902,105 shares outstanding as of December 31, 2021

 

 

 

 

 

 

Additional paid-in capital

 

 

415,454

 

 

 

408,795

 

Accumulated deficit

 

 

(344,843

)

 

 

(316,675

)

Treasury stock

 

 

(952

)

 

 

(952

)

Total stockholders’ equity

 

 

69,659

 

 

 

91,168

 

Total liabilities and stockholders’ equity

 

$

181,351

 

 

$

211,498

 

 

See notes to condensed consolidated financial statements

6


Precision Biosciences, Inc.

Condensed Consolidated Statements of Operations

(In thousands, except share and per share amounts)

(Unaudited)

 

 

 

For the Three Months Ended March 31,

 

 

 

2022

 

 

2021

 

Revenue

 

$

3,317

 

 

$

16,349

 

Operating expenses

 

 

 

 

 

 

 

 

Research and development

 

 

19,972

 

 

 

25,593

 

General and administrative

 

 

10,691

 

 

 

9,498

 

Total operating expenses

 

 

30,663

 

 

 

35,091

 

Operating loss

 

 

(27,346

)

 

 

(18,742

)

Other income (expense):

 

 

 

 

 

 

 

 

Loss from equity method investments

 

 

(952

)

 

 

 

Interest expense

 

 

(42

)

 

 

 

Interest income

 

 

172

 

 

 

53

 

Total other income (expense), net

 

 

(822

)

 

 

53

 

Net loss and net loss attributable to common stockholders

 

$

(28,168

)

 

$

(18,689

)

 

 

 

 

 

 

 

 

 

Net loss per share attributable to common stockholders-

   basic and diluted

 

$

(0.46

)

 

$

(0.33

)

Weighted average shares of common stock outstanding-

   basic and diluted

 

 

61,031,775

 

 

 

56,625,024

 

 

See notes to condensed consolidated financial statements

 

 

7


 

Precision Biosciences, Inc.

Condensed Consolidated Statements of Changes in

Stockholders’ Equity

(In thousands, except share amounts)

(Unaudited)

 

 

 

 

Common Stock

 

 

Additional

Paid-In

 

 

Accumulated

 

 

Treasury

 

 

Total

Stockholder's

 

 

 

Shares

 

 

Amount

 

 

Capital

 

 

Deficit

 

 

Stock

 

 

Equity

 

Balance- January 1, 2021

 

 

53,503,124

 

 

$

 

 

$

331,450

 

 

$

(286,073

)

 

$

(952

)

 

$

44,425

 

Stock option exercises

 

 

676,791

 

 

 

 

 

 

1,297

 

 

 

 

 

 

 

 

 

1,297

 

Issuance of common stock under employee

   stock purchase plan

 

 

90,796

 

 

 

 

 

 

418

 

 

 

 

 

 

 

 

 

418

 

Share-based compensation expense

 

 

 

 

 

 

 

 

3,632

 

 

 

 

 

 

 

 

 

3,632

 

Issuance of common stock to collaboration partners

 

 

3,762,190

 

 

 

 

 

 

27,739

 

 

 

 

 

 

 

 

 

27,739

 

Net loss

 

 

 

 

 

 

 

 

-

 

 

 

(18,689

)

 

 

 

 

 

(18,689

)

Balance- March 31, 2021

 

 

58,032,901

 

 

$

 

 

$

364,536

 

 

$

(304,762

)

 

$

(952

)

 

$

58,822

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance- January 1, 2022

 

 

61,712,577

 

 

$

 

 

$

408,795

 

 

$

(316,675

)

 

$

(952

)

 

$

91,168

 

Stock option exercises

 

 

233,001

 

 

 

 

 

 

340

 

 

 

 

 

 

 

 

 

340

 

Issuance of common stock under employee

   stock purchase plan

 

 

78,060

 

 

 

 

 

 

282

 

 

 

 

 

 

 

 

 

282

 

Share-based compensation expense

 

 

 

 

 

 

 

 

4,390

 

 

 

 

 

 

 

 

 

4,390

 

Proceeds from issuance of common stock, net of issuance

cost

 

 

561,405

 

 

 

 

 

 

1,647

 

 

 

 

 

 

 

 

 

1,647

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

(28,168

)

 

 

 

 

 

(28,168

)

Balance- March 31, 2022

 

 

62,585,043

 

 

$

 

 

$

415,454

 

 

$

(344,843

)

 

$

(952

)

 

$

69,659

 

 

See notes to condensed consolidated financial statements

 

 

 

8


 

 

Precision Biosciences, Inc.

Condensed Consolidated Statements of Cash Flows

(In thousands)

(Unaudited)

 

 

 

For the Three Months Ended March 31,

 

 

 

2022

 

 

2021

 

Cash flows from operating activities:

 

 

 

 

 

 

 

 

Net loss

 

$

(28,168

)

 

$

(18,689

)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

 

 

 

 

 

Depreciation and amortization

 

 

1,968

 

 

 

2,176

 

Share-based compensation

 

 

4,390

 

 

 

3,632

 

Loss on disposal of assets

 

 

11

 

 

 

23

 

Non-cash interest expense

 

 

17

 

 

 

 

Amortization of right-of-use assets

 

 

288

 

 

 

290

 

Loss from equity method investments

 

 

952

 

 

 

 

Amortization of discount on note receivable

 

 

(87

)

 

 

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

 

 

Prepaid expenses

 

 

374

 

 

 

(619

)

Accounts receivable

 

 

 

 

 

(9,263

)

Other assets and other current assets

 

 

171

 

 

 

(6

)

Accounts payable

 

 

(374

)

 

 

221

 

Other liabilities and other current liabilities

 

 

(5,150

)

 

 

(2,146

)

Deferred revenue

 

 

(2,830

)

 

 

92,914

 

Lease liabilities and right-of-use assets

 

 

(434

)

 

 

(461

)

Net cash provided by (used in) operating activities

 

 

(28,872

)

 

 

68,072

 

Cash flows from investing activities:

 

 

 

 

 

 

 

 

Purchases of property, equipment and software

 

 

(818

)

 

 

(1,125

)

Net cash used in investing activities

 

 

(818

)

 

 

(1,125

)

Cash flows from financing activities:

 

 

 

 

 

 

 

 

Proceeds from stock option exercises

 

 

340

 

 

 

1,297

 

Proceeds from employee stock purchase plan

 

 

282

 

 

 

418

 

Proceeds from issuance of common stock to collaboration partners

 

 

 

 

 

35,000

 

Proceeds from offering of common stock, net of issuance costs

 

 

1,627

 

 

 

 

Net cash provided by financing activities

 

 

2,249

 

 

 

36,715

 

Net increase (decrease) in cash and cash equivalents

 

 

(27,441

)

 

 

103,662

 

Cash and cash equivalents—beginning of period

 

 

143,663

 

 

 

89,798

 

Cash and cash equivalents —end of period

 

$

116,222

 

 

$

193,460

 

 

 

 

 

 

 

 

 

 

Supplemental disclosures of noncash activities:

 

 

 

 

 

 

 

 

Property, equipment and software additions included in accounts payable and other current liabilities

 

$

74

 

 

$

637

 

Unsettled at-the-market issuances of common stock included in other current assets

 

$

217

 

 

 

 

See notes to condensed consolidated financial statements

 

 

9


 

 

Precision BioSciences, Inc.

Notes to Unaudited Condensed Consolidated Financial Statements (Unaudited)

 

NOTE 1:

DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Description of Business

Precision BioSciences, Inc. (the “Company”) was incorporated on January 26, 2006 under the laws of the State of Delaware and is based in Durham, North Carolina. The Company is a clinical stage gene editing company dedicated to improving life by developing ex vivo allogeneic CAR T immunotherapies and in vivo therapies for genetic and infectious diseases with the application of the Company’s wholly owned proprietary ARCUS genome editing platform.

The Company’s 100% owned subsidiary, Precision PlantSciences, Inc., was incorporated on January 4, 2012. Precision PlantSciences, Inc. amended its certificate of incorporation on January 16, 2018 to change its name to Elo Life Systems, Inc. In December 2021, the Company entered into an agreement with a syndicate of investors, pursuant to which the Company contributed substantially all of the assets of Elo Life Systems, Inc. to a newly formed entity (the “Elo Transaction”). In connection with the Elo Transaction, Elo Life Systems, Inc. amended its certificate of incorporation on December 21, 2021 to change its name back to Precision PlantSciences, Inc. in order to permit the newly formed entity (“New Elo”) to change its name to Elo Life Systems, Inc.

The Company’s 100% owned subsidiary, Precision BioSciences UK Limited, was incorporated on June 17, 2019. The accompanying condensed consolidated financial statements include the accounts of the Company and its subsidiary. Intercompany balances and transactions have been eliminated in consolidation.

Since its inception, the Company has devoted substantially all of its efforts to research and development activities, recruiting skilled personnel, developing manufacturing processes, establishing its intellectual property portfolio and providing general and administrative support for these operations. The Company is subject to a number of risks similar to those of other companies conducting high-risk, early-stage research and development of product candidates. Principal among these risks are dependence on key individuals and intellectual property, competition from other products and companies, and the technical risks associated with the successful research, development and clinical manufacturing of its product candidates. The Company’s success is dependent upon its ability to continue to raise additional capital in order to fund ongoing research and development, obtain regulatory approval of its products, successfully commercialize its products, generate revenue, meet its obligations, and, ultimately, attain profitable operations.

Management believes that, as of the time these financial statements were issued, existing cash and cash equivalents, expected operational receipts and available credit will allow the Company to fund its operating expense and capital expenditure requirements into mid-2023. In the absence of a significant source of recurring revenue, the continued viability of the Company beyond that point is dependent on its ability to continue to raise additional capital to finance its operations. There can be no assurance that the Company will be able to obtain sufficient capital to cover its costs on acceptable terms, if at all.

Unaudited Interim Financial Information

The accompanying unaudited condensed consolidated financial statements and notes have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and note disclosures normally included in the annual financial statements, prepared in accordance with accounting principles generally accepted in the U.S. (“GAAP”), have been condensed or omitted pursuant to those rules and regulations. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, filed with the SEC on March 15, 2022.

The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements. In the opinion of management, all adjustments, consisting only of normal recurring adjustments necessary for a fair presentation of the Company’s condensed consolidated financial position as of March 31, 2022 and condensed consolidated results of operations for the three months ended March 31, 2022 and 2021 and the condensed consolidated cash flows for the three months ended March 31, 2022 and 2021, have been made. The Company’s condensed consolidated results of operations for the three months ended March 31, 2022 are not necessarily indicative of the results of operations that may be expected for the year ending December 31, 2022.

10


 

Summary of Significant Accounting Policies

Revenue Recognition for Contracts with Customers

The Company’s revenues are generated primarily through collaborative research, license, development and commercialization agreements.

Accounting standards codification (“ASC”) 606, Revenue from Contracts with Customers (“ASC 606”) applies to all contracts with customers, except for contracts that are within the scope of other standards. Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation.

At contract inception, once the contract is determined to be within the scope of ASC 606, the Company evaluates the performance obligations promised in the contract that are based on goods and services that will be transferred to the customer and determines whether those obligations are both (i) capable of being distinct and (ii) distinct in the context of the contract. Goods or services that meet these criteria are considered distinct performance obligations. If both these criteria are not met, the goods and services are combined into a single performance obligation. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. Arrangements that include rights to additional goods or services that are exercisable at a customer’s discretion are generally considered options. The Company assesses if these options provide a material right to the customer and if so, these options are considered performance obligations. The exercise of a material right is accounted for as a contract modification for accounting purposes.

The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied at a point in time or over time, and if over time this is based on the use of an output or input method. For the three months ended March 31, 2022, the Company recorded cumulative catch up adjustments on its contracts with customers that decreased revenue by $1.9 million; the cumulative catch-up adjustments resulted from changes in total estimated effort required to satisfy performance obligations. During the three months ended March 31, 2022, the Company recorded $3.3 million in revenue that was included in deferred revenue as of December 31, 2021.

Invoices issued as stipulated in contracts prior to revenue recognition are recorded as deferred revenue. Amounts expected to be recognized as revenue within the 12 months following the balance sheet date are classified as deferred revenue within current liabilities in the accompanying condensed consolidated balance sheets. Amounts not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as noncurrent deferred revenue. Amounts recognized as revenue, but not yet invoiced are generally recognized as contract assets in the other current assets line item in the accompanying condensed consolidated balance sheets.

Milestone Payments – If an arrangement includes development and regulatory milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company’s or the licensee’s control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received and therefore revenue recognized is constrained as management is unable to assert that a reversal of revenue would not be probable. The transaction price is then allocated to each performance obligation on a relative standalone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint, and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenues and earnings in the period of adjustment.

Royalties – For arrangements that include sales-based royalties, including milestone payments based on a level of sales, which are the result of a customer-vendor relationship and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation linked to some or all of the royalty has been satisfied or partially satisfied. To date, the Company has not recognized any royalty revenue resulting from any of its licensing arrangements.

Significant Financing Component – In determining the transaction price, the Company adjusts consideration for the effects of the time value of money if the timing of payments provides the Company with a significant benefit of financing. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the licensees and the transfer of the promised goods or services to the licensees will be one year or less. The Company

11


 

assessed each of its revenue arrangements in order to determine whether a significant financing component exists and concluded that a significant financing component does not exist in any of its arrangements.

Collaborative Arrangements – The Company has entered into collaboration agreements, which are within the scope of ASC 606, to discover, develop, manufacture and commercialize product candidates. The terms of these agreements typically contain multiple promises or obligations, which may include: (1) licenses, or options to obtain licenses, to use the Company’s technology, (2) research and development activities to be performed on behalf of the collaboration partner, and (3) in certain cases, services in connection with the manufacturing of preclinical and clinical material. Payments the Company receives under these arrangements typically include one or more of the following: non-refundable, upfront license fees; option exercise fees; funding of research and/or development efforts; clinical and development, regulatory, and sales milestone payments; and royalties on future product sales.

The Company analyzes its collaboration arrangements to assess whether the collaboration agreements are within the scope of ASC 808, Collaborative Arrangements (“ASC 808”) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. For collaboration arrangements within the scope of ASC 808 that contain multiple elements, the Company first determines which elements of the collaboration are deemed to be within the scope of ASC 808 and those that are more reflective of a vendor-customer relationship and, therefore, are within the scope of ASC 606. For elements of collaboration arrangements that are accounted for pursuant to ASC 808, an appropriate recognition method is determined and applied consistently, generally by analogy to ASC 606. For those elements of the arrangement that are accounted for pursuant to ASC 606, the Company applies the five-step model described above.

For additional discussion of accounting for collaboration revenues, see Note 9, “Collaboration and License Agreements.”

NOTE 2:

STOCKHOLDERS’ EQUITY

Capital Structure

On April 1, 2019, the Company filed an amendment to its amended and restated certificate of incorporation pursuant to which, among other things, the Company increased its authorized shares to 210,000,000 shares of capital stock, of which 200,000,000 shares were designated as $0.000005 par value common stock and 10,000,000 shares were designated as $0.0001 par value preferred stock.

NOTE 3:

SHARE-BASED COMPENSATION

The Company previously granted stock options under its 2006 Stock Incentive Plan (the “2006 Plan”) and its 2015 Stock Incentive Plan (the “2015 Plan”). As of March 31, 2022 there were 2,466,385 stock options outstanding under the 2006 Plan and 2015 Plan and no remaining stock options available to be granted under such plans.

On March 12, 2019, the Company’s board of directors adopted, and, on March 14, 2019 the Company’s stockholders approved, the Precision BioSciences, Inc. 2019 Incentive Award Plan (“2019 Plan”) and the 2019 Employee Stock Purchase Plan (“2019 ESPP”), both of which became effective on March 27, 2019.

The 2019 Plan provides for the grant of incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock, restricted stock units and other share-based awards. The number of shares available for issuance under the 2019 Plan initially equaled 4,750,000 shares of common stock. The 2019 Plan provides for an annual increase to the number of shares of common stock available for issuance on the first day of each calendar year beginning January 1, 2020 and ending on and including January 1, 2029 by an amount equal to the lesser of (i) 4% of the aggregate number of shares of common stock outstanding on the final day of the immediately preceding calendar year and (ii) such smaller number of shares of common stock as determined by the board of directors. As of March 31, 2022, the aggregate number of shares available for issuance under the 2019 Plan has been increased by 6,589,999 pursuant to this provision. Any shares that are subject to awards outstanding under the Company’s 2006 Plan and 2015 Plan as of the effective date of the 2019 Plan that expire, lapse, or are terminated, exchanged for cash, surrendered, repurchased, or canceled without having been fully exercised or forfeited, to the extent so unused, will become available for award grants under the 2019 Plan. As of March 31, 2022, 1,435,206 shares were available to be issued under the 2019 Plan. The 2019 Plan had 8,569,187 stock options and 2,320,362 restricted stock units (“RSUs”) outstanding as of March 31, 2022.

Up to 525,000 shares of the Company’s common stock were initially reserved for issuance under the 2019 ESPP. The 2019 ESPP provides for an annual increase to the number of shares available for issuance on the first day of each calendar year beginning January 1, 2020 and ending on and including January 1, 2029 by an amount equal to the lesser of (i) 1% of the shares outstanding on the final day of the immediately preceding calendar year and (ii) such smaller number of shares as is determined by our board of directors. As of March 31, 2022, the aggregate number of shares available for issuance under the 2019 ESPP has been increased by 1,647,499 shares pursuant to this provision. No more than 5,250,000 shares of our common stock may be issued under our 2019 ESPP. The

12


 

purchase price of the shares under the 2019 ESPP, in the absence of a contrary designation, will be 85% of the lower of the fair market value of our common stock on the first trading day of the offering period or on the purchase date. As of March 31, 2022, the Company had issued 331,175 shares under the 2019 ESPP. As of March 31, 2022, 1,841,324 shares were available to be issued under the 2019 ESPP. The Company recognized share-based compensation expense related to the ESPP of less than $0.1 million during the three months ended March 31, 2022 and 2021.

On August 9, 2021, the Company’s board of directors approved the adoption of the Precision BioSciences, Inc. 2021 Employment Inducement Incentive Award Plan (“Inducement Award Plan”).

The Inducement Award Plan provides for the grant of non-qualified stock options, stock appreciation rights, restricted stock, RSUs and other share-based awards to newly hired employees who have not previously been an employee or member of the board, or an employee who is being rehired following a bona fide period of non-employment by the Company. No more than 3,000,000 shares of the Company’s common stock may be issued under the Inducement Award Plan. As of March 31, 2022, 2,125,792 shares were available to be issued under the Inducement Award Plan. The Inducement Award Plan had 850,000 stock options and 24,208 RSUs outstanding as of March 31, 2022.

The Company recorded employee and nonemployee share-based compensation expense as follows (in thousands):

 

 

 

Three Months Ended March 31,

 

 

 

2022

 

 

2021

 

Employee

 

$

3,554

 

 

$

3,278

 

Nonemployee

 

 

836

 

 

 

354

 

 

 

$

4,390

 

 

$

3,632

 

 

Share-based compensation expense is included in the following line items in the condensed consolidated statements of operations (in thousands):

 

 

 

Three Months Ended March 31,

 

 

 

2022

 

 

2021

 

Research and development

 

$

2,012

 

 

$

2,082

 

General and administrative

 

 

2,378

 

 

 

1,550

 

 

 

$

4,390

 

 

$

3,632

 

Determining the appropriate fair value model to measure the fair value of the stock option grants on the date of grant and the related assumptions requires judgment. The fair value of each stock option grant is estimated using a Black-Scholes option-pricing model on the date of grant as follows:

 

 

 

Three Months Ended March 31,

 

 

 

2022

 

 

2021

 

Estimated dividend yield

 

 

0.00

%

 

 

0.00

%

Weighted-average expected stock price volatility

 

 

78.47

%

 

 

73.69

%

Weighted-average risk-free interest rate

 

 

1.85

%

 

 

0.66

%

Expected term of options (in years)

 

 

6.08

 

 

 

6.43

 

Weighted-average fair value per option

 

$

2.73

 

 

$

8.32

 

The expected volatility rates are estimated based on the actual volatility of a peer group comprised of the Company and other comparable public companies over the expected term. The expected term represents the average time that stock options that vest are expected to be outstanding. The Company does not have sufficient history of exercising stock options to estimate the expected term of employee stock options and thus utilizes a weighted value considering actual history and estimated expected term based on the midpoint of final vest date and expiration date. The risk-free rate is based on the United States Treasury yield curve at the time of grant for the expected term of the option.

13


 

The following table summarizes activity in the Company’s stock option plans for the three months ended March 31, 2022:

 

 

 

Outstanding Option Shares

 

 

Weighted-Average Exercise Price

 

Balance as of January 1, 2022

 

 

9,920,314

 

 

$

9.28

 

Granted

 

 

2,938,074

 

 

 

3.98

 

Exercised

 

 

(233,001

)

 

 

1.46

 

Forfeited/canceled

 

 

(739,815

)

 

 

10.00

 

Balance as of March 31, 2022

 

 

11,885,572

 

 

$

8.08

 

The intrinsic value of stock options exercised was $0.5 million and $6.8 million during the three months ended March 31, 2022 and 2021, respectively.

During the three months ended March 31, 2022, the Company granted 1,620,098 RSUs with a grant date fair value of $6.3 million. The fair value of each award was determined based on the market price of the Company’s common stock on the date of grant. The fair value of the RSUs will be recognized as expense over the requisite vesting period.

The following table summarizes the Company’s RSU activity for the three months ended March 31, 2022:

 

 

RSU Awards

 

 

Weighted-Average Grant Date Fair Value

 

Unvested RSUs as of January 1, 2022

 

 

773,503

 

 

 

11.29

 

Granted

 

 

1,620,098

 

 

$

3.88

 

Forfeited

 

 

(49,031

)

 

 

10.44

 

Vested

 

 

 

 

 

 

Unvested RSUs as of March 31, 2022

 

 

2,344,570

 

 

$

6.19

 

There was approximately $43.2 million of total unrecognized compensation cost related to unvested stock options and RSUs as of March 31, 2022, which is expected to be recognized over a weighted-average period of 2.8 years.

NOTE 4:

COMMITMENTS AND CONTINGENCIES

Litigation

The Company is subject to various legal matters and claims in the ordinary course of business. Although the results of legal proceedings and claims cannot be predicted with certainty, in the opinion of management, there are currently no such known matters that will have a material effect on the consolidated financial condition, results of operations or cash flows of the Company.

COVID-19 Pandemic

In March 2020, the World Health Organization designated the outbreak of the novel strain of coronavirus known as COVID-19 as a global pandemic. The Company has taken steps in line with guidance from the U.S. Centers for Disease Control and Prevention and the State of North Carolina to protect the health and safety of its employees and the community.

The Company is working closely with its clinical sites, physician partners and the patient community to monitor and manage the ongoing impact of the COVID-19 pandemic and variants thereof. The Company remains committed to its clinical programs and development plans, however, disruptions, competing resource demands and safety concerns caused by the COVID-19 pandemic and variants thereof have caused, and are likely to continue to cause, delays in the Company’s clinical trial site activation and impacted its ability to enroll patients. The Company may also experience other difficulties, disruptions or delays in conducting preclinical studies, initiating, enrolling, conducting or completing its planned and ongoing clinical trials or supply chain disruptions, and the Company may incur other unforeseen costs as a result. While the extent to which the COVID-19 pandemic and variants thereof may continue to impact the Company’s future results will depend on future developments, the pandemic and associated economic impacts could result in a material impact to the Company’s future financial condition, results of operations and cash flows.

Servier Program Purchase Agreement

On April 9, 2021, the Company entered into a program purchase agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier (collectively, “Servier”), pursuant to which the Company reacquired all of its global development and commercialization rights previously granted to Servier pursuant to the Development and Commercial License Agreement by and between Servier and the Company, dated February 24, 2016, as amended (the “Servier Agreement”), and mutually terminated the Servier Agreement (the “Program Purchase Agreement”).

14


 

The Program Purchase Agreement requires the Company to make certain payments to Servier based on the achievement of regulatory and commercial milestones for each product, and a low- to mid-single-digit percentage royalty (subject to certain reductions) based on net sales of approved products, if any, resulting from any continued development and commercialization of the programs by the Company, for a period not to exceed ten years after first commercial sale of the applicable product in the United States or certain countries in Europe. If the Company enters into specified product partnering transactions, the Program Purchase Agreement requires the Company to pay to Servier a portion of certain consideration received pursuant to such product partnering transactions in lieu of the foregoing milestones (with the exception of a one-time clinical phase development milestone) and royalties.

Regulatory and Commercial Milestones

Management assessed the likelihood of each of the regulatory and commercial milestones included in the Program Purchase Agreement in accordance with ASC 450, Contingencies (“ASC 450”). If the assessment of a contingency indicates that it is probable that the milestone will be achieved and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company’s condensed consolidated financial statements. Accordingly, a $10.0 million financial contract liability was included in the condensed consolidated balance sheets as of March 31, 2022 and December 31, 2021.

Product Partnering Transaction Consideration Due to Servier

Per the terms of the Program Purchase Agreement, should the Company enter into a product partnering transaction with respect to any of the targets previously nominated by Servier, the Company will pay Servier a percentage of the proceeds received. In accordance with ASC 450 management concluded that the amount of proceeds due to Servier as a result of a future product partnering transaction, if any, cannot be reasonably estimated as of the date of this Quarterly Report on Form 10-Q. As such, no contingency for this provision was included in the condensed consolidated financial statements as of March 31, 2022 or December 31, 2021.

Leases

The Company has operating leases for real estate in North Carolina and does not have any finance leases.

Many of the Company’s leases contain options to renew and extend lease terms and options to terminate leases early. Reflected in the right-of-use asset and lease liabilities on the Company’s condensed consolidated balance sheet are the periods provided by renewal and extension options that the Company is reasonably certain to exercise, as well as the periods provided by termination options that the Company is reasonably certain to not exercise.

The Company has existing leases that include variable lease payments that are not included in the right-of-use asset and lease liabilities and are reflected as an expense in the period incurred. Such payments primarily include common area maintenance charges. These variable lease payments are paid separately from rent based on actual costs incurred and therefore are not included in the right-of-use assets and lease liabilities but rather reflected as an expense in the period incurred.

Future lease payments under non-cancelable operating leases with terms of greater than one year as of March 31, 2022, were as follows:

(in thousands)

 

March 31, 2022

 

2022 (excluding the three months ended March 31, 2022)

 

$

1,703

 

2023

 

 

2,323

 

2024

 

 

1,594

 

2025

 

 

529

 

2026

 

 

545

 

2027 and beyond

 

 

372

 

Total lease payments

 

 

7,066

 

Less: imputed interest

 

 

865

 

Total operating lease liabilities

 

$

6,201

 

 

Supply Agreements

The Company enters into contracts in the normal course of business with contract manufacturing organizations (“CMOs”) for the manufacture of clinical trial materials and contract research organizations (“CROs”) for clinical trial services. These agreements provide for termination at the request of either party with less than one-year notice and are, therefore, cancelable contracts and, if canceled, are not anticipated to have a material effect on the condensed consolidated financial condition, results of operations, or cash flows of the Company.

15


 

NOTE 5:

DEBT

Revolving Line

Pursuant to the terms of the loan and security agreement with Pacific Western Bank (the “Revolving Line”) the Company may request advances on a revolving line of credit of up to an aggregate principal of $30.0 million.

The Revolving Line matures on June 23, 2023. All outstanding principal amounts are due on the maturity date. The Company must also maintain an aggregate balance of unrestricted cash at Pacific Western Bank (“PWB”) (not including amounts in certain specified accounts) equal to or greater than $10.0 million. The interest rate under the Revolving Line is a variable annual rate equal to the greater of (a) 2.75% above the Prime Rate (as defined in the Revolving Line), or (b) 6.00%. As of March 31, 2022, the stated interest rate on the Revolving line was 6.25% and the effective interest rate was 7.03%.

In December 2021, the Company borrowed $2.5 million under the Revolving Line. As of March 31, 2022, $2.5 million was outstanding under the Revolving Line. The Company was in compliance with its financial covenants under the Revolving Line as of March 31, 2022.

NOTE 6:

Income Taxes

The Company estimates an annual effective tax rate of 0% for the year ending December 31, 2022 as the Company incurred losses for the three months ended March 31, 2022 and expects to continue to incur losses through the remainder of fiscal year ending December 31, 2022, resulting in an estimated net loss for both financial statement and tax purposes for the year ending December 31, 2022. Therefore, no federal or state income taxes are expected and none have been recorded at this time. Income taxes have been accounted for using the liability method.

Due to the Company's history of losses since inception, there is not enough evidence at this time to support that the Company will generate future income of a sufficient amount and nature to utilize the benefits of its net deferred tax assets. Accordingly, the deferred tax assets have been reduced by a full valuation allowance, since the Company does not currently believe that realization of its deferred tax assets is more likely than not.

As of March 31, 2022, the Company had no unrecognized income tax benefits that would reduce the Company’s effective tax rate if recognized.

NOTE 7:

FAIR VALUE MEASUREMENTS

The carrying amounts of the Company’s accounts receivable, accounts payable, and accrued expenses and other current liabilities, approximate their respective fair values due to their short-term nature. The Company uses a three-tier fair value hierarchy to classify and disclose all assets and liabilities measured at fair value on a recurring basis and to minimize the use of unobservable inputs when determining their fair value. The three tiers are defined as follows:

Level 1—Observable inputs based on unadjusted quoted prices in active markets for identical assets or liabilities

Level 2—Inputs, other than quoted prices in active markets, that are observable either directly or indirectly

Level 3—Unobservable inputs for which there is little or no market data, which require the Company to develop its own assumptions

Cash Equivalents

As of March 31, 2022 and December 31, 2021, the Company held an insignificant amount of cash equivalents which were composed of investments in money market funds. The Company classifies investments in money market funds within Level 1 of the fair value hierarchy as the prices are available from quoted prices in active markets.

Investment in iECURE

In August 2021, the Company entered into an Equity Issuance Agreement with iECURE, Inc. (“iECURE”), pursuant to which iECURE granted the Company partial equity ownership in iECURE (the “iECURE equity”) as partial consideration for a license to use the Company’s PCSK9-directed ARCUS nuclease to insert genes into the PCSK9 locus to develop treatments for four pre-specified rare genetic diseases (the “PCSK9 license”). On issuance, the Company accounted for the iECURE equity at fair value under ASC 825, Financial Instruments (“ASC 825”). Accordingly, the Company adjusts the carrying value of the iECURE equity to fair value each reporting period with any changes in fair value recorded to other income (expense). There was no assessed change in the fair value of the iECURE equity during the three months ended March 31, 2022.

16


 

The Company classifies the iECURE equity within Level 3 of the fair value hierarchy as the assessed fair value was based on significant unobservable inputs given iECURE equity is not traded on a public exchange. For additional discussion of accounting for the iECURE Development and License agreement (as defined below) and the iECURE Equity Issuance Agreement (as defined below), refer to Note 9, “Collaboration and License Agreements.”

The following represents assets and liabilities measured at fair value on a recurring basis by the Company (in thousands):

March 31, 2022

 

Fair Value

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

Assets:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

12

 

 

$

12

 

 

$

 

 

$

 

Investment in iECURE

 

 

3,091

 

 

 

 

 

 

 

 

 

3,091

 

 

 

 

3,103

 

 

 

12

 

 

 

 

 

 

3,091

 

 

December 31, 2021

 

Fair Value

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

Assets:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

12

 

 

$